Literature DB >> 24747741

Is Alzheimer's disease a systemic disease?

Jill K Morris1, Robyn A Honea2, Eric D Vidoni3, Russell H Swerdlow4, Jeffrey M Burns5.   

Abstract

Although Alzheimer's disease (AD) is the most common neurodegenerative disease, the etiology of AD is not well understood. In some cases, genetic factors explain AD risk, but a high percentage of late-onset AD is unexplained. The fact that AD is associated with a number of physical and systemic manifestations suggests that AD is a multifactorial disease that affects both the CNS and periphery. Interestingly, a common feature of many systemic processes linked to AD is involvement in energy metabolism. The goals of this review are to 1) explore the evidence that peripheral processes contribute to AD risk, 2) explore ways that AD modulates whole-body changes, and 3) discuss the role of genetics, mitochondria, and vascular mechanisms as underlying factors that could mediate both central and peripheral manifestations of AD. Despite efforts to strictly define AD as a homogeneous CNS disease, there may be no single etiologic pathway leading to the syndrome of AD dementia. Rather, the neurodegenerative process may involve some degree of baseline genetic risk that is modified by external risk factors. Continued research into the diverse but related processes linked to AD risk is necessary for successful development of disease-modifying therapies.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Exercise; Metabolism; Mitochondria; Physical activity

Mesh:

Year:  2014        PMID: 24747741      PMCID: PMC4126236          DOI: 10.1016/j.bbadis.2014.04.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  220 in total

1.  Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults.

Authors:  Earl S Ford
Journal:  Epidemiology       Date:  2002-09       Impact factor: 4.822

2.  Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study.

Authors:  K I Erickson; C A Raji; O L Lopez; J T Becker; C Rosano; A B Newman; H M Gach; P M Thompson; A J Ho; L H Kuller
Journal:  Neurology       Date:  2010-10-13       Impact factor: 9.910

3.  Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults.

Authors:  Francesca M Filbey; Kelly J Slack; Trey P Sunderland; Robert M Cohen
Journal:  Neuroreport       Date:  2006-10-23       Impact factor: 1.837

4.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

5.  Age and fitness effects on EEG, ERPs, visual sensitivity, and cognition.

Authors:  R E Dustman; R Y Emmerson; R O Ruhling; D E Shearer; L A Steinhaus; S C Johnson; H W Bonekat; J W Shigeoka
Journal:  Neurobiol Aging       Date:  1990 May-Jun       Impact factor: 4.673

6.  Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice.

Authors:  O Wirths; G Multhaup; C Czech; V Blanchard; S Moussaoui; G Tremp; L Pradier; K Beyreuther; T A Bayer
Journal:  Neurosci Lett       Date:  2001-06-22       Impact factor: 3.046

7.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.

Authors:  A Lorenzo; B Razzaboni; G C Weir; B A Yankner
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

8.  Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.

Authors:  Virginie Rhein; Xiaomin Song; Andreas Wiesner; Lars M Ittner; Ginette Baysang; Fides Meier; Laurence Ozmen; Horst Bluethmann; Stefan Dröse; Ulrich Brandt; Egemen Savaskan; Christian Czech; Jürgen Götz; Anne Eckert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

9.  Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort.

Authors:  Anna-Maija Tolppanen; Tiia Ngandu; Ingemar Kåreholt; Tiina Laatikainen; Minna Rusanen; Hilkka Soininen; Miia Kivipelto
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

View more
  73 in total

1.  Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Authors:  Patricia Del Cerro; Carolina Alquézar; Fernando Bartolomé; Pedro González-Naranjo; Concepción Pérez; Eva Carro; Juan A Páez; Nuria E Campillo; Ángeles Martín-Requero
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

2.  Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Authors:  Miren Ettcheto; Elena Sánchez-López; Yaiza Gómez-Mínguez; Henrry Cabrera; Oriol Busquets; Carlos Beas-Zarate; Maria Luisa García; Eva Carro; Gemma Casadesus; Carme Auladell; Manuel Vázquez Carrera; Jaume Folch; Antoni Camins
Journal:  Mol Neurobiol       Date:  2018-02-05       Impact factor: 5.590

Review 3.  Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.

Authors:  Heeyoung Lee; EunYoung Kim
Journal:  Arch Pharm Res       Date:  2020-09-09       Impact factor: 4.946

4.  Increased Serum Acylated Ghrelin Levels in Patients with Mild Cognitive Impairment.

Authors:  Xi Cao; Min Zhu; Yan He; Wenzheng Chu; Yifeng Du; Heng Du
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 5.  Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.

Authors:  Charles C Caldwell; Jia Yao; Roberta Diaz Brinton
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

6.  Rationale and methods for a multicenter clinical trial assessing exercise and intensive vascular risk reduction in preventing dementia (rrAD Study).

Authors:  Amanda N Szabo-Reed; Eric Vidoni; Ellen F Binder; Jeffrey Burns; C Munro Cullum; William P Gahan; Aditi Gupta; Linda S Hynan; Diana R Kerwin; Heidi Rossetti; Ann M Stowe; Wanpen Vongpatanasin; David C Zhu; Rong Zhang; Jeffrey N Keller
Journal:  Contemp Clin Trials       Date:  2019-03-01       Impact factor: 2.226

7.  On the analysis of complex biological supply chains: From Process Systems Engineering to Quantitative Systems Pharmacology.

Authors:  Rohit T Rao; Megerle L Scherholz; Clara Hartmanshenn; Seul-A Bae; Ioannis P Androulakis
Journal:  Comput Chem Eng       Date:  2017-06-03       Impact factor: 3.845

8.  Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease.

Authors:  Jill K Morris; Roxanne Adeline Z Uy; Eric D Vidoni; Heather M Wilkins; Ashley E Archer; John P Thyfault; John M Miles; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Quantitative Systems Pharmacology: A Framework for Context.

Authors:  Ioannis P Androulakis
Journal:  Curr Pharmacol Rep       Date:  2016-04-08

10.  Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults.

Authors:  Jennifer S Rabin; Zahra Shirzadi; Walter Swardfager; Bradley J MacIntosh; Aaron Schultz; Hyun-Sik Yang; Rachel F Buckley; Jennifer R Gatchel; Dylan Kirn; Jeremy J Pruzin; Trey Hedden; Nir Lipsman; Dorene M Rentz; Sandra E Black; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  Neurobiol Aging       Date:  2020-03-07       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.